Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

類似資料

• Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
  著者:: Badoux, Xavier C., 等
  出版事項: (2011)
• Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab
  著者:: Langerak, Anton W., 等
  出版事項: (2019)
• Fludarabine, Cyclophosphamide, Mitoxantrone plus Rituximab (FCM-R) in Frontline CLL < 70 Years
  著者:: Faderl, Stefan, 等
  出版事項: (2009)
• Risk categories and refractory CLL in the era of chemoimmunotherapy
  著者:: Zenz, Thorsten, 等
  出版事項: (2012)
• Fludarabine plus cyclophosphamide prolongs disease-free survival in CLL
  出版事項: (2007)